Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

October 10, 2027

Study Completion Date

October 10, 2027

Conditions
OsteosarcomaSoft Tissue Sarcoma
Interventions
BIOLOGICAL

DIT309 cell injection

3+3 dose escalation design: Dose Level 1: 4.0×10\^6/kg CAR+ T cells;Dose Level 2: 1.0×10\^7/kg CAR+ T cells;Dose Level 3: 2.0×10\^7/kg CAR+ T cells.

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Tcelltech Inc.

INDUSTRY